<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255435</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 408-C-1402</org_study_id>
    <nct_id>NCT02255435</nct_id>
  </id_info>
  <brief_title>RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe</brief_title>
  <official_title>A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Friedreich's Ataxia Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Friedreich's ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat
      expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first
      intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological
      consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster
      biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an
      increased sensitivity to oxidative stress.

      A hallmark of Friedreich's ataxia is impairment of antioxidative defense mechanisms, which
      play a major role in disease progression. Studies have demonstrated that nuclear factor
      erythroid-derived 2-related factor 2 (Nrf2) signaling is grossly impaired in patients with
      Friedreich's ataxia. Therefore, the ability of omaveloxolone (RTA 408) to activate Nrf2 and
      induce antioxidant target genes is hypothesized to be therapeutic in patients with
      Friedreich's ataxia.

      This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone
      (RTA 408) in the treatment of patients with Friedreich's ataxia.

      Part 1: The first part of this study will be a randomized, placebo-controlled, double-blind,
      dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in
      patients with Friedreich's ataxia.

      Part 2: The second part of this study is a randomized, placebo-controlled, double-blind,
      parallel-group study to evaluate the safety and efficacy of omaveloxolone (RTA 408) 150 mg in
      patients with Friedreich's ataxia. Patients enrolled in Part 2 will be randomized 1:1 to
      receive omaveloxolone (RTA 408) 150 mg or placebo.

      Extension: The extension will assess long-term safety and tolerability of omaveloxolone (RTA
      408) in qualified patients with Friedreich's ataxia following completion of Part 1 or Part 2.
      Patients will not be unblinded to study treatment in Part 1 or Part 2 upon entering the
      extension study. Patients will receive open-label omaveloxolone (RTA 408) at 150 mg once
      daily.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the change in the modified Friedreich's ataxia rating scale (FARS)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the change of peak workload (in watts/kg) during exercise testing</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 2.5 and 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 10 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 300 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 150 mg taken orally once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 2.5 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 2.5 and 5 mg</arm_group_label>
    <other_name>RTA 408 Capsules 2.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 5 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 2.5 and 5 mg</arm_group_label>
    <other_name>RTA 408 capsules, 5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 10 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 10 mg</arm_group_label>
    <other_name>RTA 408 capsules, 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 20 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 20 mg</arm_group_label>
    <other_name>RTA 408 capsules, 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 40 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 40 mg</arm_group_label>
    <other_name>RTA 408 capsules, 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 80 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 80 mg</arm_group_label>
    <other_name>RTA 408 capsules, 48 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 160 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 160 mg</arm_group_label>
    <other_name>RTA 408 capsules, 160 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 300 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 300 mg</arm_group_label>
    <other_name>RTA 408 capsules, 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 150 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 150 mg</arm_group_label>
    <other_name>RTA 408 capsules, 150 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have genetically confirmed Friedreich's ataxia

          2. Have a modified FARS score ≥20 and ≤80

          3. Be male or female and ≥16 years of age and ≤40 years of age

          4. Have no changes to exercise regimen within 30 days prior to Study Day 1 and be willing
             to remain on the same exercise regimen during the 16-week study period

          5. Have the ability to complete maximal exercise testing

          6. Be able to swallow capsules

        Exclusion Criteria:

          1. Have uncontrolled diabetes (HbA1c &gt;11.0%)

          2. Have B-type natriuretic peptide value &gt;200 pg/mL

          3. Have a history of clinically significant left-sided heart disease and/or clinically
             significant cardiac disease

          4. Have known active fungal, bacterial, and/or viral infection, including human
             immunodeficiency virus or hepatitis virus (B or C)

          5. Have known or suspected active drug or alcohol abuse

          6. Have clinically significant abnormalities of clinical hematology or biochemistry,
             including but not limited to elevations greater than 1.5 times the upper limit of
             normal of aspartate aminotransferase, or alanine aminotransferase

          7. Have any abnormal laboratory test value or serious pre-existing medical condition
             that, in the opinion of the investigator, would put the patient at risk by study
             enrollment

          8. Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to
             take any of these drugs during the time of study participation:

               1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide,
                  midazolam, sildenafil)

               2. Moderate or strong inhibitors or inducers of cytochrome P450 3A4 (e.g.,
                  carbamazepine, phenytoin, ciprofloxacin, grapefruit juice)

               3. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)

          9. Have participated in any other interventional clinical study within 30 days prior to
             Study Day 1

         10. Have a cognitive impairment that may preclude ability to comply with study procedures

         11. Prior participation in a trial with omaveloxolone (RTA 408)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Fisher</last_name>
      <phone>310-206-8153</phone>
      <email>adfisher@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Perlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida - Neurology</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aika Konn</last_name>
      <phone>352-273-6003</phone>
      <email>aika.konn@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>SH Subramony, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USF Ataxia Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Fink-Irizarry</last_name>
      <email>paolaf@health.usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Shaw</last_name>
      <email>jshaw@helath.usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Theresa Zesiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Neurology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky McMurray, RN</last_name>
      <phone>404-712-7013</phone>
      <email>rebecca.s.mcmurray@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Wilmot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Stead Family Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey McDaniel</last_name>
      <email>corey-mcdaniel@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Neurology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabitha Alexander</last_name>
      <phone>614-685-3030</phone>
      <email>tabitha.alexander@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Chad Hoyle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Hauser</last_name>
      <phone>267-426-9738</phone>
      <email>hauserl@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>David Lynch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneieve Tai</last_name>
      <phone>61 3 8341 6374</phone>
      <email>geneieve.tai@mcri.edu.au</email>
    </contact>
    <investigator>
      <last_name>Martin Delatycki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SN Sigrid Zimmermann</last_name>
      <email>sigrid.zimmermann@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Sylvia Boesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Campinas</name>
      <address>
        <city>São Paulo</city>
        <zip>13083</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Fernanda Ribeiro Bittar</last_name>
      <email>mafe@fcm.unicamp.br</email>
    </contact>
    <investigator>
      <last_name>Marcondes Franaca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Institute Carlo Besta</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <email>moxie@reatapharma.com</email>
    </contact>
    <investigator>
      <last_name>Caterina Mariotti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College of London</name>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mila Resuello-Dauti</last_name>
      <phone>0203 4484531</phone>
      <email>Mila.Resuello-Dauti@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Paola Giunti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTA 408</keyword>
  <keyword>RTA 408 Capsules</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Mitochondrial dysfunction</keyword>
  <keyword>omaveloxolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

